Bench to Bedside: Chemistry of Health Care

Cancer-Targeted Delivery of Therapeutics and Diagnostics (#393)

Cancer targeted therapy aims to deliver anti-cancer therapeutics and probes, including chemoagents, proteins, nucleic acids, and contrast agents, to a patient in a manner that increases the concentration of the therapeutics at the cancer site relative to other parts of the body. In this regard, tumor targeted delivery of therapeutics and diagnostics is being used to prolong, localize, and target those agents to the diseased tissue thereby increasing the therapeutic index of the therapeutics with reduced toxic side effects. One common strategy is to employ ligands interacting with target molecular markers in cancer tissues and cancer cells such as antibody fragments, affibodies, peptides, and aptamers. Another approach is to tune the therapeutics and diagnostics delivery carriers to undero significant physico-chemical properties, resulting in stimuli-responsive release and activation of the payloads. This symposium will include presentations on topics related to the chemistry of cancer targeting ligands and cancer-responsive delivery strategies, but not limited to, such as: novel probes and probe strategies for targeting cancers, development of drug conjugates, combined diagnosis and therapy (theranostics), and other novel systems in this emerging area. This symposium will also invite studies that bridges between basic research and clinical translation.
Last update: Dec 28, 2015